Navigation Links
Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
Date:8/4/2008

PhenoSense(R) Integrase Now Enables Clinicians to Monitor Activity of New

Class of Potent Antiretroviral Drugs

SOUTH SAN FRANCISCO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced the launch of its PhenoSense(R) Integrase assay, built on Monogram's proprietary technology platform, PhenoSense(R). The assay directly measures the susceptibility of HIV to a new and potent class of integrase inhibitor drugs that blocks viral replication by preventing viral genes from integrating into the DNA of newly infected cells. Together with PhenoSense GT(R), PhenoSense Integrase provides the most complete picture of resistance to antiretroviral therapies.

PhenoSense Integrase along with other Monogram assays were used to support the clinical trials of the first commercially-available integrase inhibitor, Merck's Isentress(TM) (raltegravir), which received U.S. Food and Drug Administration (FDA) approval in October 2007. In Merck's phase III BENCHMRK trials, Monogram's PhenoSenseGT was used to select optimized drug regimens in the placebo and Isentress-containing treatment arms while PhenoSense Integrase was used to identify and characterize Isentress resistant viruses in treatment failures. The company is also actively involved in the clinical evaluation of Gilead's integrase inhibitor candidate, elvitegravir, currently in Phase III studies. In addition to drug resistance, PhenoSense Integrase also measures reductions in viral replication capacity associated with integrase inhibitor resistance that may help characterize viral fitness.

"Using new antiretroviral drugs correctly today, including HIV integrase inhibitors, is critically important since the pipeline for
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
10. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... a multi-arm Phase 1 study of MM-141, a bispecific ... in an oral session by Dr. Mansoor Saleh ... Research Annual Meeting in Philadelphia, PA. ... MM-141 as a monotherapy and in combination with everolimus ...
(Date:4/21/2015)... , April 21, 2015  Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... that Dr. Mark W. Sawicki , ... 3rd Annual BioLogistics Summit in San ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 PRC ... sponsor and exhibit at the ACRP 2015 Global Conference ... City, Utah. The Association of Clinical Research Professionals (ACRP) ... research conference solely focused on the conduct of clinical ... and development, and widely recognized industry certifications. , The ...
(Date:4/21/2015)... Mo. (PRWEB) April 21, 2015 A ... HOLLOWAY AMERICA is slated to discuss its custom fabrication ... present its reimagined website, which launched just prior to ... and Thurs. (April 21, 22 and 23) at the ... 12,000 representatives of the world’s largest and most innovative ...
Breaking Biology Technology:First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3
... a biotechnology company developing orally-available antiviral therapeutics, today announced that ... Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and ... Adenovirus Disease Following H em a ... T ransplantation [HSCT]).The company also announced that the U.S. ...
... in cat litter and other applications. The extraordinary properties of ... its scarcity in the Earth,s crust: only a few mines ... Spain, the world,s biggest exporter of this material. Sepiolite ... to filter and purify wine, but our understanding at the ...
... July 12, 2011 The J. R. Simplot ... all-native biotechnology platform for improving crops, leading to ...   http://photos.prnewswire.com/prnh/20110712/SF33047LOGO )   Innate™ Technology ... with a plant,s own genes to enhance desirable ...
Cached Biology Technology:Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 2Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 3Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 4Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 5Cat litter to become an edible product? 2
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts ...
(Date:3/18/2015)... -- As mobile payments become more prevalent amongst ... apps continue to be introduced into the market place at ... industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... ), Apple Inc. (NASDAQ: AAPL ), Google Inc. ... FB ) NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... to the prevailing view, the hormone leptin, which is critical ... mass and suppress appetite by acting mainly through serotonin pathways ... Cell by Yale School of Medicine researchers and ... that leptin acts primarily in the hypothalamus. "Our ...
... French . Nineteen McGill University researchers ... mathematics are among the 181 newly appointed or renewed Canada ... Minister of State (Science and Technology.) McGill received ... a total of $17,600,000, the largest amount received by any ...
... A NASA team is developing a transparent coating that ... prevent dirt from sticking to the surfaces of spaceflight ... Materials engineers at NASA,s Goddard Space Flight Center ... coating that can survive the harsh space environment and ...
Cached Biology News:Researchers identify new brain pathway for regulating weight and bone mass 2McGill garners 19 Canada Research Chairs and more than $17 million in funding 2McGill garners 19 Canada Research Chairs and more than $17 million in funding 3Lotus-plant-inspired dust-busting shield to protect space gear 2Lotus-plant-inspired dust-busting shield to protect space gear 3
Request Info...
ANTI STENOTROPHOMONAS MALTOPHILIA...
... Phoretix 2D, Expression and Evolution supports data ... gel analysis studies in determining differential protein ... component Oracle data base plug ... client software). Supports advanced statistical ...
Request Info...
Biology Products: